本研究将客观的美国麻醉医师协会 (ASA) 和成人合并症评估-27 (ACE-27) 评分与主观的东部肿瘤合作组表现状态 (ECOG PS) 进行比较，以预测患者的结果。我们回顾性分析了头颈部鳞状细胞2008 年 6 月至 2015 年 6 月在慕尼黑慕尼黑大学接受辅助（化疗）放疗的癌症患者。该研究重点关注患者预后之间的关联；治疗失败；已知的危险因素（包括人乳头瘤病毒 [HPV] 状态和肿瘤分期）；以及合并症指数 ECOG-PS、ASA 评分和 ACE-27。采用Kaplan-Meier法和Cox比例风险模型进行生存分析并确定独立危险因素。共分析302例患者，其中175例接受同步化疗。中位随访时间为 61.8 个月，中位诊断年龄为 61 岁。 3年和5年总生存率（OS）和无病生存率（DFS）分别为70.5%/60.2%和64.7%/57.6%。在单变量和多变量分析中，ACE-27 和 ASA 均与 OS 显着相关，而 ECOG-PS 仅在单变量分析中显着。 ASA和ACE-27评分也与局部和局部区域复发显着相关，但在多变量模型中只有HPV状态和肿瘤分期具有显着性。ACE-27和ASA评分有效地对患者在头颈癌辅助放疗中的风险进行了分类，证明比 ECOG-PS 更能预测总生存期。这些结果强调了客观合并症评估的重要性，并建议进一步的前瞻性研究。© 2024。作者。

This study compares the objective American Society of Anesthesiologists (ASA) and Adult Comorbidity Evaluation-27 (ACE-27) scores with the subjective Eastern Cooperative Oncology Group performance status (ECOG PS) for patient outcome prediction.We retrospectively analyzed head and neck squamous cell carcinoma patients treated with adjuvant (chemo)radiotherapy at the LMU Munich from June 2008 to June 2015. The study focused on associations between patient outcomes; treatment failures; known risk factors (including human papillomavirus [HPV] status and tumor stage); and the comorbidity indices ECOG-PS, ASA score, and ACE-27. The Kaplan-Meier method and Cox proportional hazards model were used for survival analysis and identifying independent risk factors.A total of 302 patients were analyzed, 175 received concurrent chemotherapy. Median follow-up was 61.8 months, and median age at diagnosis was 61 years. The 3‑ and 5‑year overall survival (OS) and disease-free survival (DFS) rates were 70.5%/60.2% and 64.7%/57.6%, respectively. Both ACE-27 and ASA showed significant correlations with OS in univariate and multivariate analyses, while ECOG-PS was significant only in univariate analysis. ASA and ACE-27 scores were also significantly correlated with local and locoregional recurrence, but only HPV status and tumor stage were significant in multivariate models.ACE-27 and ASA score effectively categorize patients' risks in adjuvant radiotherapy for head and neck cancer, proving more predictive of overall survival than ECOG-PS. These results underscore the importance of objective comorbidity assessment and suggest further prospective studies.© 2024. The Author(s).